Navidea biopharmaceuticals announces end-of-phase 2 type b meeting request granted by the fda to discuss ongoing clinical program in rheumatoid arthritis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the u.s. food and drug administration (“fda”) has granted the company's request for an end-of-phase 2 type b meeting to discuss its ongoing program in rheumatoid arthritis (“ra”) and advancement to the pivotal phase 3 trial. the meeting will take place on septembe
NAVB Ratings Summary
NAVB Quant Ranking